Will the Novo-Catalent merger be challenged under the new Trump administration? A former FTC policy director thinks so.

On Wednesday, Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $61 which represents a slight increase of $0.25 or 0.41% from the prior close of $60.75. The stock opened at $60.95 and ...

Adds Reuters report. Catalent (NYSE:CTLT) rose 2.2% amid reports that the European Union's antitrust regulator will likely ...

Charles Schwab Investment Management Inc. boosted its stake in Catalent, Inc. (NYSE:CTLT – Free Report) by 1.1% during the ...

Contract manufacturing revenues in the pharmaceutical finished dose sector witnessed a significant slowdown over the past ...

Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter ...

Pharma leaders hoping for a friendlier merger environment after the Trump administration grabs the keys to the White House ...

Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed ...

Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug ...

The growing inclination for biologics and biosimilars is driving the sterile injectable contract manufacturing market.New ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the ...

Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its ...